Last Update 09 Apr 26
Fair value Decreased 0.60%CL: 2030 Plan Execution And Margins Will Shape 2026 Setup
Analysts have trimmed the Colgate-Palmolive fair value estimate by about $0.58 to $96.68, reflecting slightly softer revenue growth assumptions, a modestly lower future P/E, and mixed recent research that includes both reduced price targets and an upgrade tied to confidence in the 2030 plan and ongoing margin resilience.
Analyst Commentary
Recent Street research on Colgate-Palmolive shows a mix of optimism around the long-term plan and caution around nearer term cost and valuation risks. Price targets have moved in both directions, and ratings have shifted as analysts reassess execution on the 2030 plan, margin durability, and input cost pressures.
Bullish Takeaways
- Bullish analysts point to management's 2030 plan and related presentations as a key support for longer term growth ambitions, highlighting company specific actions on product development, market positioning, and operational initiatives.
- Some research cites confidence in business momentum tied to this plan, which supports higher fair value assumptions and, in several cases, upward revisions to price targets across large brokers.
- There is a focus on Colgate-Palmolive's exposure to emerging markets as a potential growth driver over time, which these analysts see as a differentiator within the staples group.
- A few bullish reports frame recent target increases as reflecting stronger conviction in execution on cost management and product initiatives rather than a broad sector move alone.
Bearish Takeaways
- Bearish analysts have cited higher oil based input costs as a reason for downgrades, pointing to possible pressure on gross margins and earnings if cost inflation is not fully offset.
- Recent price target cuts suggest some concern that prior valuation multiples may be difficult to sustain, especially where P/E assumptions had previously embedded a high premium within staples.
- There is caution that, despite earlier optimism, the balance of risks around sales growth and valuation looks more even at current share levels, prompting rating downgrades or more neutral stances.
- Some research ties lower targets to sector level adjustments, implying that part of the recent reappraisal is driven by broader staples sector moves rather than company specific upside alone.
What’s in the News
- Colgate Optic White launched the NEW Colgate Optic White Pro Series Toothpaste, featuring a Hydrogen Peroxide Complex and Dual Whitening Technology that targets both surface and deep-set stains, with 5% hydrogen peroxide and an enamel safe formula designed for daily use at home. The product is available in multiple variants at major retailers for an MSRP of US$9.99 for a 3 oz tube (Product related announcement).
- The Board of Directors approved a quarterly common stock cash dividend of US$0.53 per share, up from US$0.52, effective in the second quarter of 2026. The dividend is scheduled for payment on May 15, 2026 to shareholders of record on April 20, 2026, implying an annualized rate of US$2.12 per share versus US$2.08 previously (Dividend announcement).
- The company issued full year 2026 guidance, targeting net sales up 2% to 6%, including a low single digit positive foreign exchange impact. Organic sales growth is targeted at 1% to 4% after an approximately 20 basis point effect from exiting the private label pet food business. The company also outlined expectations for GAAP gross margin expansion, higher advertising spend as a percentage of net sales, and double digit EPS growth (Guidance update).
- From October 1, 2025 to December 31, 2025, Colgate-Palmolive repurchased 5,073,677 shares, or 0.63% of shares, for US$398.48m. This completed a total buyback of 10,960,706 shares, or 1.36%, for US$914.24m under the program announced on March 20, 2025 (Buyback update).
Valuation Changes
- Fair Value: Trimmed slightly from $97.26 to $96.68 per share, a reduction of about $0.58.
- Discount Rate: Held steady at 6.98%, indicating no change in the assumed cost of capital.
- Revenue Growth: Adjusted slightly lower from 3.80% to 3.76%, reflecting a modestly softer topline outlook in the model.
- Net Profit Margin: Edged higher from 15.45% to 15.47%, implying a small improvement in expected profitability.
- Future P/E: Reduced marginally from 26.21x to 26.05x, signaling a slightly lower valuation multiple applied to forward earnings.
Key Takeaways
- Expansion in oral care and focus on emerging markets, with premiumization and innovation, drive sustained volume growth and strengthen global brand positioning.
- Investment in AI, digital transformation, and productivity boosts efficiencies, enabling reinvestment into growth and supporting stable margins and resilience against market cycles.
- Persistent cost pressures, cautious consumer behavior, and competitive challenges in major markets are constraining margin expansion, topline growth, and long-term revenue prospects.
Catalysts
About Colgate-Palmolive- Manufactures and sells consumer products in the United States and internationally.
- Expansion and premiumization of core oral care lines like Colgate Total, coupled with the roll-out of complementary products across 75 markets, are set to capture increased value from emerging middle-class consumers and rising health/hygiene awareness globally-supporting top-line organic sales acceleration and improved pricing power.
- Emerging markets such as India, Latin America, and Southeast Asia-where rising incomes and urbanization are growing the addressable customer base-remain a strategic focus with stepped-up innovation, brand investment, and price tiering, sustaining long-term volume and revenue growth.
- Continued investments in AI, digital transformation, and omnichannel demand generation are expected to enhance operational efficiency, customer reach, and data-driven marketing, translating into greater sales effectiveness and margin resilience.
- Productivity and restructuring initiatives ($200–$300 million over three years) are designed to free up resources for innovation, digital, and R&D investments, enabling incremental margin expansion and additional reinvestment for growth.
- Category stabilization and long-term brand strength, particularly in daily-use, trusted segments (oral care, pet nutrition), position Colgate-Palmolive to outperform peers as consumer confidence rebounds, supporting consistent earnings growth and de-risking revenue from cyclical downturns.
Colgate-Palmolive Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Colgate-Palmolive's revenue will grow by 3.8% annually over the next 3 years.
- Analysts assume that profit margins will increase from 10.5% today to 15.5% in 3 years time.
- Analysts expect earnings to reach $3.5 billion (and earnings per share of $4.49) by about April 2029, up from $2.1 billion today.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 26.1x on those 2029 earnings, down from 32.2x today. This future PE is greater than the current PE for the US Household Products industry at 20.1x.
- Analysts expect the number of shares outstanding to decline by 1.09% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 6.98%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- Consumer caution and category softness in key markets like North America, Brazil, and India could persist due to elevated food inflation and macroeconomic uncertainty, potentially constraining volume growth and revenue.
- Rising raw material and packaging costs, particularly for palm oil and fats, are significantly impacting gross margin, and relief is uncertain, posing ongoing pressure on net margins and profitability.
- Increased focus on price pack architecture and value offerings in response to cautious consumers and lower category inflation may limit the company's ability to drive premium pricing, potentially compressing margins and slowing topline growth.
- Company performance in China and India is being challenged by local market dynamics, with China's Hawley & Hazel business requiring significant repositioning in a highly competitive e-commerce environment and India experiencing urban market sluggishness, both of which could hinder long-term revenue growth in these important markets.
- Continued exposure to private label competition, especially in the pet food category and key emerging markets, along with the exit from private label production, could negatively impact reported sales growth and overall earnings during the transition period.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $96.68 for Colgate-Palmolive based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $105.0, and the most bearish reporting a price target of just $85.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $22.8 billion, earnings will come to $3.5 billion, and it would be trading on a PE ratio of 26.1x, assuming you use a discount rate of 7.0%.
- Given the current share price of $85.55, the analyst price target of $96.68 is 11.5% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Colgate-Palmolive?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.